CClinicalTrials.gg
Sign In
WithdrawnNCT04411316Updated Sep 9, 2021

Catheter-directed Thrombolysis Compared to Anticoagulation Alone for Acute Primary Iliofemoral Deep Venous Thrombosis

A Phase 4 interventional study of Catheter directed thrombolysis plus anticoagulation and Anticoagulation in Deep Venous Thrombosis and Post Thrombotic Syndrome, sponsored by University of Toledo Health Science Campus. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-09.

Sponsored by University of Toledo Health Science Campus · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Zero Patients met criteria

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2019, registered May 2020).
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Post-thrombotic syndrome (PTS) is a complication that can develop after deep vein thrombosis (DVT) of the lower extremities. PTS can occur at various times after the initial episode, but usually manifests within two years of initial DVT onset. Early and more complete thrombus clearance is believed by many to relieve venous outflow obstruction, preserve valvular function and reduce venous hypertension. Two previously published randomized controlled trials, the CAVENT trial and the ATTRACT trial, were larger and designed to investigate the efficacy of CDT. However, both of these trials included patients with iliofemoral as well as femoro-popliteal deep vein thrombosis. Our study will be limited to patients with iliofemoral deep vein thrombosis to assess whether Pharmacomechanical catheter-directed thrombolysis (PCDT) therapy utilizing AngioJet and tPA can safely and effectively reduce post thrombotic syndrome after 24 months.

Read the detailed description

Patients with Iliofemoral DVT are theoretically at the highest risk for development of PRS given involvement of the major drainage pathway of both superficial femoral and deep femoral veins. This would not only affect the primary venous drainage, but would also compromise the ability to develop efficient collateral pathways. This creates higher chances of developing post-thrombotic syndrome (PTS). The proposed trial would utilize Angiojet thrombectomy followed by catheter directed thrombolysis and Anticoagulation compared to Anticoagulation alone. To assess whether Pharmacomechanical catheter-directed thrombolysis (PCDT) therapy utilizing AngioJet and tPA for the treatment of iliofemoral deep venous thrombosis can safely and effectively reduce post thrombotic syndrome after 24 months.

02

Conditions studied

  • Deep Venous Thrombosis
  • Post Thrombotic Syndrome
03

In context

Thrombosis

1,508 studies on the registry are indexed under Thrombosis; 239 are open to participants now.

Browse Thrombosis studies →

Lead sponsor

University of Toledo Health Science Campus is the lead sponsor of 35 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Age>18 and younger than 75
  2. Symptomatic, proximal deep-vein thrombosis involving the Iliofemoral vein from 12/01/2019 to 12/01/2022

Exclusion criteria

Exclusion Criteria:

  1. Age less than 18 years or greater than 75 years.
  2. Symptom duration > 14 days for the DVT episode in the index leg (i.e. non-acute DVT).
  3. In the index leg: established PTS, or previous symptomatic DVT within the last 2 years.
  4. In the contralateral (non-index) leg: symptomatic acute DVT a) involving the popliteal and/or tibial veins; or b) for which thrombolysis is planned as part of initial therapy.
  5. Limb-threatening circulatory compromise.
  6. PE with hemodynamic compromise (i.e. hypotension).
  7. Inability to tolerate PCDT procedure due to severe dyspnea or acute systemic illness.
  8. Allergy, hypersensitivity, or thrombocytopenia from heparin, rt-PA, or iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used.
  9. Hemoglobin \< 9.0 mg/dl, INR > 1.6 before warfarin was started, or platelets \< 100,000 /ml.
  10. Moderate renal impairment in diabetic patients (estimated GFR \< 60 ml/min) or severe renal impairment in non-diabetic patients (estimated GFR \< 30 ml/min).
  11. Active bleeding, recent (\< 3 months) GI bleeding, severe liver dysfunction, bleeding diathesis.
  12. Recent (\< 3 months) internal eye surgery or hemorrhagic retinopathy; recent (\< 10 days) major surgery, cataract surgery, trauma, CPR, obstetrical delivery, or other invasive procedure.
  13. History of stroke or intracranial/intraspinal bleed, tumor, vascular malformation, aneurysm.
  14. Active cancer (metastatic, progressive, or treated within the last 6 months). Exception: patients with non-melanoma primary skin cancers are eligible to participate in the study.
  15. Severe hypertension on repeated readings (systolic > 180mmHg or diastolic > 105 mmHg).
  16. Pregnant (positive pregnancy test, women of childbearing potential must be tested).
  17. Recently (\< 2 years or chronic non-ambulatory status.
  18. Use of a thienopryridine antiplatelet drug (except clopidogrel) in the last 5 days.
  19. Life expectancy \< 2 years or chronic non-ambulatory status.
  20. Inability to provide informed consent or to comply with study assessments (e.g. due to cognitive impairment or geographic distance).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pharmacomechanical thrombolysis plus anticoagulation

    This group of patients will receive Pharmacomechanical catheter-directed thrombolysis (PCDT) plus Anticoagulation. PCDT will be AngioJet along with alteplase. Anticoagulation will be heparin only

    Combination Product: Catheter directed thrombolysis plus anticoagulation

  • Active comparator
    Anticoagulation

    This group of patients will receive standard anticoagulation only. Anticoagulation will be Heparin only

    Drug: Anticoagulation

Interventions

  • Combination productCatheter directed thrombolysis plus anticoagulation

    Patients will be randomized to pharmacomechanical catheter directed thrombolysis plus anticoagulation. PCDT will be AngioJet along with alteplase.

    Also known as: Pharmacomechanical thrombolysis

  • DrugAnticoagulation

    Patients will receive anticoagulation alone. Anticoagulation will be heparin only.

06

What researchers measure

Primary outcomes

  1. Post-thrombotic syndrome at any time between 6-month and 24-month.

    Occurrence of post-thrombotic syndrome at any time between 6-month and 24-month after procedure by Villata score (Villata score \>5 or more), or if patient underwent an unplanned endovascular procedure to treat venous symptoms. The variables in villata scores are pain, cramps, heaviness, parasthesia, pruritus, pretibial edema, skin induration, hyperpigmentation, pain during calf compression, venous ectasia and redness. The Villata score ranges 0-45. Villata score \<5 means no post-thrombotic syndrome. Villata score 5-9 mild post-thrombotic syndrome. Villata score 10-14 means moderate post-thrombotic syndrome. Villata score ≥15 or presence of an ulcer indicates severe post-thrombotic syndrome. The more is the score the worse is the disease.

    Time frame: 6-24 months

Secondary outcomes

  1. Post-thrombotic syndrome at 6 months.

    Occurrence of post-thrombotic syndrome at 6 months measured by Villata score (Villalta score was 5 or higher).

    Time frame: 6 months

  2. Post-thrombotic syndrome at 12 months.

    Occurrence of post-thrombotic syndrome at 12 months measured by Villata score (Villalta score was 5 or higher).

    Time frame: 12 months

  3. Post-thrombotic syndrome at 18 months.

    Occurrence of post-thrombotic syndrome at 18 months measured by Villata score (Villalta score was 5 or higher).

    Time frame: 18 months

  4. Post-thrombotic syndrome at 24 months.

    Occurrence of post-thrombotic syndrome at 24 months measured by Villata score (Villalta score was 5 or higher).

    Time frame: 24 months

  5. Villalta scale at 6 months

    The severity of the post-thrombotic syndrome to be evaluated at 6 months with the use of the Villalta scale

    Time frame: 6 months

  6. Villalta scale at 12 months

    The severity of the post-thrombotic syndrome to be evaluated at 12 months with the use of the Villalta scale.

    Time frame: 12 months

  7. Villalta scale at 18 months

    The severity of the post-thrombotic syndrome to be evaluated at 18 months with the use of the Villalta scale.

    Time frame: 18 months

  8. Villalta scale at 24 months

    The severity of the post-thrombotic syndrome to be evaluated at 18 months with the use of the Villalta scale.

    Time frame: 24 months

  9. Venous Clinical Severity Score at 6 months

    The severity of the post-thrombotic syndrome to be evaluated at 6 months with the use of the Venous Clinical Severity Score.

    Time frame: 6 months

  10. Venous Clinical Severity Score at 12 months

    The severity of the post-thrombotic syndrome to be evaluated at 12 months with the use of the Venous Clinical Severity Score.

    Time frame: 12 months

  11. Venous Clinical Severity Score at 18 months

    The severity of the post-thrombotic syndrome to be evaluated at 18 months with the use of the Venous Clinical Severity Score.

    Time frame: 18 months

  12. Venous Clinical Severity Score at 24 months

    The severity of the post-thrombotic syndrome to be evaluated at 24 months with the use of the Venous Clinical Severity Score.

    Time frame: 24 months

  13. Health-Related Quality of Life AT 6 months

    Health-Related Quality of Life measured by Venous Disease-Specific Quality of Life

    Time frame: 6 months

  14. Health-Related Quality of Life at 12 months.

    Health-Related Quality of Life measured by Venous Disease-Specific Quality of Life at 12 months.

    Time frame: 12 months

  15. Health-Related Quality of Life at 18 months.

    Health-Related Quality of Life measured by Venous Disease-Specific Quality of Life at 18 months.

    Time frame: 18 months

  16. Health-Related Quality of Life at 24 months.

    Health-Related Quality of Life measured by Venous Disease-Specific Quality of Life at 24 months.

    Time frame: 24 months

  17. Health-Related Quality of Life at 6 months.

    Health-Related Quality of Life measured by Generic Quality of Life at 6 months.

    Time frame: 6 months

  18. Health-Related Quality of Life at 12 months.

    Health-Related Quality of Life measured by Generic Quality of Life at 12 months

    Time frame: 12 months

  19. Health-Related Quality of Life at 18 months.

    Health-Related Quality of Life measured by Generic Quality of Life at 18 months.

    Time frame: 18 months

  20. Health-Related Quality of Life at 24 months.

    Health-Related Quality of Life measured by Generic Quality of Life at 24 months.

    Time frame: 24 months

  21. Health-Related Quality of Life at 6 months.

    Health-Related Quality of Life measured by Administration of QOL Measures at 6 months.

    Time frame: 6 months

  22. Health-Related Quality of Life at 12 months.

    Health-Related Quality of Life measured by Administration of QOL Measures at 12 months.

    Time frame: 12 months

  23. Health-Related Quality of Life at 18 months.

    Health-Related Quality of Life measured by Administration of QOL Measures at 18 months.

    Time frame: 18 months

  24. Health-Related Quality of Life at 24 months.

    Health-Related Quality of Life measured by Administration of QOL Measures at 24 months.

    Time frame: 24 months

  25. Treatment Failures that are Not PTS.

    Treatment Failures that are Not PTS (defined as one or more of the following during the 24 months post randomization: 1) the patient underwent an unplanned endovascular or surgical intervention for the treatment of severe symptomatic venous disease in the index leg within the first 24 months after randomization (2) the subject underwent an amputation in the index leg anytime within 24 months after randomization; or (3) the subject developed venous gangrene in the index leg within the first 24 months after randomization.

    Time frame: 6-24 months

  26. Severity of presenting DVT Symptoms at 6 months

    Severity of presenting DVT Symptoms (Leg pain severity measured by pain scale) at 6 months

    Time frame: 6 months

  27. Severity of presenting DVT Symptoms at 12 months

    Severity of presenting DVT Symptoms (Leg pain severity measured by pain scale) at 12 months

    Time frame: 12 months

  28. Severity of presenting DVT Symptoms at 18 months

    Severity of presenting DVT Symptoms (Leg pain severity measured by pain scale) at 18 months

    Time frame: 18 months

  29. Severity of presenting DVT Symptoms at 24 months

    Severity of presenting DVT Symptoms (Leg pain severity measured by pain scale) at 24 months

    Time frame: 24 months

  30. Severity of presenting DVT Symptoms at 6 months

    Severity of presenting DVT Symptoms (Leg swelling measured by measuring calf swelling) at 6 months

    Time frame: 6 months

  31. Severity of presenting DVT Symptoms at 12 months

    Severity of presenting DVT Symptoms (Leg swelling measured by measuring calf swelling) at 12 months

    Time frame: 12 months

  32. Severity of presenting DVT Symptoms at 18 months

    Severity of presenting DVT Symptoms (Leg swelling measured by measuring calf swelling) at 18 months

    Time frame: 18 months

  33. Severity of presenting DVT Symptoms at 24 months

    Severity of presenting DVT Symptoms (Leg swelling measured by measuring calf swelling) at 24 months

    Time frame: 24 months

  34. Degree of Resolution of Thrombus with PCDT at 6 months.

    Degree of Resolution of Thrombus with PCDT (Assessed by two sets of venograms in PCDT arm, one baseline venogram of the proximal veins (popliteal vein through infrarenal IVC) obtained after initial catheter insertion into the venous system before PCDT; and one the final venogram of the proximal veins obtained after PCDT and any adjunctive procedures, before sheath removal. Marder score will be used to quantify clot burden. Marder score range 0-24, with 0 representing no thrombus and 24 representing complete thrombosis). The degree of thrombus elimination (% change in pre-PCDT and post-PCDT Marder score) will be calculated.

    Time frame: 6 months

  35. Degree of Resolution of Thrombus with PCDT at 12 months.

    Degree of Resolution of Thrombus with PCDT (Assessed by two sets of venograms in PCDT arm, one baseline venogram of the proximal veins (popliteal vein through infrarenal IVC) obtained after initial catheter insertion into the venous system before PCDT; and one the final venogram of the proximal veins obtained after PCDT and any adjunctive procedures, before sheath removal. Marder score will be used to quantify clot burden. Marder score range 0-24, with 0 representing no thrombus and 24 representing complete thrombosis). The degree of thrombus elimination (% change in pre-PCDT and post-PCDT Marder score) will be calculated.

    Time frame: 12 months

  36. Degree of Resolution of Thrombus with PCDT at 18 months.

    Degree of Resolution of Thrombus with PCDT (Assessed by two sets of venograms in PCDT arm, one baseline venogram of the proximal veins (popliteal vein through infrarenal IVC) obtained after initial catheter insertion into the venous system before PCDT; and one the final venogram of the proximal veins obtained after PCDT and any adjunctive procedures, before sheath removal. Marder score will be used to quantify clot burden. Marder score range 0-24, with 0 representing no thrombus and 24 representing complete thrombosis). The degree of thrombus elimination (% change in pre-PCDT and post-PCDT Marder score) will be calculated.

    Time frame: 18 months

  37. Degree of Resolution of Thrombus with PCDT at 24 months.

    Degree of Resolution of Thrombus with PCDT (Assessed by two sets of venograms in PCDT arm, one baseline venogram of the proximal veins (popliteal vein through infrarenal IVC) obtained after initial catheter insertion into the venous system before PCDT; and one the final venogram of the proximal veins obtained after PCDT and any adjunctive procedures, before sheath removal. Marder score will be used to quantify clot burden. Marder score range 0-24, with 0 representing no thrombus and 24 representing complete thrombosis). The degree of thrombus elimination (% change in pre-PCDT and post-PCDT Marder score) will be calculated.

    Time frame: 24 months

07

Study locations

1 site
  • University of Toledo Medical Center
    Toledo, Ohio 43614, United States
08

References and documents

Publications

  • Vedantham S. Valvular dysfunction and venous obstruction in the post-thrombotic syndrome. Thromb Res. 2009;123 Suppl 4:S62-5. doi: 10.1016/S0049-3848(09)70146-X. PubMed 19303507 ↗
  • DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT. Clinicaltrial.gov
  • Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis. 2009 Nov;28(4):465-76. doi: 10.1007/s11239-009-0309-3. Epub 2009 Feb 18. PubMed 19224134 ↗
  • Kahn SR, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M, Ginsberg JS. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008 Nov 18;149(10):698-707. doi: 10.7326/0003-4819-149-10-200811180-00004. PubMed 19017588 ↗
  • Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, Gupta DK, Prandoni P, Vedantham S, Walsh ME, Weitz JI; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014 Oct 28;130(18):1636-61. doi: 10.1161/CIR.0000000000000130. Epub 2014 Sep 22. No abstract available. Erratum In: Circulation. 2015 Feb 24;131(8):e359. doi: 10.1161/CIR.0000000000000185. PubMed 25246013 ↗
  • Comerota AJ, Grewal N, Martinez JT, Chen JT, Disalle R, Andrews L, Sepanski D, Assi Z. Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. J Vasc Surg. 2012 Mar;55(3):768-73. doi: 10.1016/j.jvs.2011.10.032. Epub 2012 Jan 24. Erratum In: J Vasc Surg. 2012 May;55(5):1547. PubMed 22277690 ↗
  • Schweizer J, Kirch W, Koch R, Elix H, Hellner G, Forkmann L, Graf A. Short- and long-term results after thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol. 2000 Oct;36(4):1336-43. doi: 10.1016/s0735-1097(00)00863-9. PubMed 11028492 ↗
  • Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med. 1984 Mar;76(3):393-7. doi: 10.1016/0002-9343(84)90656-9. PubMed 6367454 ↗
  • Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg. 2002 Sep;24(3):209-14. doi: 10.1053/ejvs.2002.1665. PubMed 12217281 ↗
  • Bashir R, Zack CJ, Zhao H, Comerota AJ, Bove AA. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. JAMA Intern Med. 2014 Sep;174(9):1494-501. doi: 10.1001/jamainternmed.2014.3415. PubMed 25047081 ↗
  • Enden T, Haig Y, Klow NE, Slagsvold CE, Sandvik L, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012 Jan 7;379(9810):31-8. doi: 10.1016/S0140-6736(11)61753-4. Epub 2011 Dec 13. PubMed 22172244 ↗
  • Haig Y, Enden T, Grotta O, Klow NE, Slagsvold CE, Ghanima W, Sandvik L, Hafsahl G, Holme PA, Holmen LO, Njaaastad AM, Sandbaek G, Sandset PM; CaVenT Study Group. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016 Feb;3(2):e64-71. doi: 10.1016/S2352-3026(15)00248-3. Epub 2016 Jan 6. PubMed 26853645 ↗
  • Vedantham S, Goldhaber SZ, Julian JA, Kahn SR, Jaff MR, Cohen DJ, Magnuson E, Razavi MK, Comerota AJ, Gornik HL, Murphy TP, Lewis L, Duncan JR, Nieters P, Derfler MC, Filion M, Gu CS, Kee S, Schneider J, Saad N, Blinder M, Moll S, Sacks D, Lin J, Rundback J, Garcia M, Razdan R, VanderWoude E, Marques V, Kearon C; ATTRACT Trial Investigators. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med. 2017 Dec 7;377(23):2240-2252. doi: 10.1056/NEJMoa1615066. PubMed 29211671 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04411316
Lead sponsor
University of Toledo Health Science Campus
Responsible party
Ehab Eltahawy, MD (Associate professor of Medicine, University of Toledo Health Science Campus) — Principal investigator
First posted
Jun 2, 2020
Start date
Dec 19, 2019
Primary completion
Dec 19, 2022 (estimated)
Completion
Dec 19, 2022 (estimated)
Last update
Sep 9, 2021

Study contacts

Ehab A Eltahawy, MD
principal investigator · University of Toledo Health Science Campus

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Thrombosis→

Other studies from this sponsor

University of Toledo Health Science Campus

Start the discussion